Long-term follow up of REDO study of ultra-low dose RTX (200mg vs 500mg vs 1000mg every 6 months) in RA. All doses appeared similarly effective, but also had similar adverse events. Potentially cost and time saving. Abstr#1443 #ACR21 @RheumNow https://t.co/0FRYPUOMpY

#ACR21 Ab#1443 by @NathandBroeder: Ultra-low dose RTX in RA? ⭐️RTX 200mg ▶️High retention in all groups- only 7 pts (6%) switched therapy. No diff in disease activity bw 200/500/1000mg Great initial data, want more data on CD19/20, Ifns, etc. @Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/X1jCcw3h0I

• https://bit.ly/3qk9MB2

?Save $ and ⬇️bad #COVID19 outcomes by using ultra low dose #Rituximab in #RheumatoidArthritis retreatmet after responding to 1g. Not quite same benefit and sl earlier repeat dosing. @RheumNow #ACR21 #ACRBest abst#1443 Impt study https://t.co/SFZKpTYJXP

Way to go Texas! #ACRknowledgebowl winners #GullsofGalveston when they answered the final jeopardy round: This monogenic dz can mimic Behcet’s syndrome and occurs due to mutation in TNFAIP3 @utmbhealth #ACR21 @rheumnow ...What is ...Haploinsufficiency A20? https://t.co/ExjKqtykVy

Dr Sherbini @james_gwinnutt @khyrich on baseline factors associated with nausea and alopecia with MTX. Alcohol use (modifiable!) and 👩 assoc with both. Disease activity with nausea. HAQ with alopecia. Abstr#1444 #ACR21 @RheumNow #ACRBest https://t.co/e0BG9omnEv

axSpA and Depression 71 axSpA patients surveyed Abnormal HADs-D scores ▶️Significantly worse BASDAI and AQoL scores Severe PHQ-9 scores ▶️worse BASDAI, BASFI and ASQoL Abst# 1305 #ACR21 @RheumNow https://t.co/Sf2Rm6z7ln

#ACR21 Ab#1444 @AhmadSherbini. Factors ass w/ nausea & alopecia in MTX ⭐️Nausea & alopecia: ♀️, 🥃, activity score are risk factors ▶️EtOH highlights importance of folic acid in these pts! @Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/lxB2z2lXtu

• https://bit.ly/3qk9MB2

Rheumatology Research Foundation Lecture: Learning lessons from @Google to harness #omics to better understand #RA #ACR21 @RheumNow @RheumResearch https://t.co/NVAe2Rqo1O

Love-hate relationship with #methotrexate. Side effects are common ex nausea/GI in 1/3 and alopecia in women. ?if you ask do you get more AES. Tough to treat especially SEs are early. ?Coach pt to help w persistence abst1444# @RheumNow #ACR21 https://t.co/NDQDVz8lk2

Dr Stewart @TonyMerriman2 report in 16,000 patients that repeat serum urate testing not superior to single measure in predicting incident gout over 9 years. Makes sense in general, maybe different in those with medication changes etc? Abstr#1449 #ACR21 @RheumNow https://t.co/69NofMNuB8

@NamrataRheum on outcomes in RA patients on RTX who get COVID-19. ⬆️hospitalisation, ICU, mech ventilation, but not mortality (in this cohort) Abstr#1445 #ACR21 @RheumNow https://t.co/8RcrzTdEb0

Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia ⭐️Anemia resolution associated with improved clinical status #ACR21 #ACRBest Abs#1331 @RheumNow https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed

• Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthrit…

#Uveitis is the most ⬆ freq xtra-articular manifestation in axSpA. What factors are assoc'd w/AAU attacks? 👁‍🗨Active disease 👁‍🗨History of AAU Bottomline: Treat axSpA, treat uveitis = better outcomes. @RheumNow #ACR21 abs1314 https://t.co/O0kHulwJoP

#ACR21 Ab#1445. RTX & #covid19 outcomes ⭐️RTX ass. w/ ⬆️ COVID hospitalization, ICU admission, and ventilation ▶️ We need huge caution in pts that have not been vax'ed before RTX 💉💉 @Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/R7jNb066m6

• https://bit.ly/3qk9MB2

Yup, another large database shows more #hospitalizations with #RheumatoidArthritis with #rituximab but NOT higher mortality in matched analysis. Abst#1445 #ACR21 @RheumNow https://t.co/9XV8iX10sA